ANIX vs. MIST, PRPH, ACRS, ETON, CLSD, ONCY, SPRO, CMRX, QTTB, and ORMP
Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Milestone Pharmaceuticals (MIST), ProPhase Labs (PRPH), Aclaris Therapeutics (ACRS), Eton Pharmaceuticals (ETON), Clearside Biomedical (CLSD), Oncolytics Biotech (ONCY), Spero Therapeutics (SPRO), Chimerix (CMRX), Q32 Bio (QTTB), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical preparations" industry.
Anixa Biosciences (NASDAQ:ANIX) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Anixa Biosciences has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Milestone Pharmaceuticals received 57 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 67.57% of users gave Milestone Pharmaceuticals an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
In the previous week, Anixa Biosciences had 7 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 8 mentions for Anixa Biosciences and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.87 beat Anixa Biosciences' score of -0.36 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.
Anixa Biosciences currently has a consensus price target of $12.00, indicating a potential upside of 300.00%. Milestone Pharmaceuticals has a consensus price target of $10.75, indicating a potential upside of 532.35%. Given Milestone Pharmaceuticals' higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Anixa Biosciences.
29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 22.6% of Anixa Biosciences shares are held by insiders. Comparatively, 10.4% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Anixa Biosciences' return on equity of -44.09% beat Milestone Pharmaceuticals' return on equity.
Anixa Biosciences has higher earnings, but lower revenue than Milestone Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Milestone Pharmaceuticals beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks.
Get Anixa Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anixa Biosciences Competitors List
Related Companies and Tools
